Does Medicare Cover Weight-Loss Medication? 2026 Guide

Creator: Dr. Tran Le, MD, DABOM
Published: 2026-06-23T13:36:41+00:00

If you're on Medicare and wondering whether your plan will help pay for a GLP-1 medication, it depends on why it's prescribed. A new federal demonstration puts certain weight-loss drugs within reach for a $50 monthly copay.

This is educational information, not personal medical advice. Our clinic is physician-led by Dr. Tran Le, MD, DABOM (triple board-certified in Obesity Medicine, Addiction Medicine, and Occupational and Environmental Medicine), and we help patients in Texas and Utah sort through these options every week.

Does Medicare cover weight-loss medication in 2026?

Traditional Medicare Part D does not cover a GLP-1 prescribed solely for weight loss. A temporary federal program now offers a path to coverage for some people.

Federal law has blocked this for decades. Medicare Part D plans cannot cover medications prescribed for weight loss, among several other "excluded" categories. The exclusion dates back to the Medicare Modernization Act of 2003, which created Part D and barred coverage for drugs aimed at weight gain or weight loss.

In 2024, CMS proposed reinterpreting that exclusion to allow coverage of anti-obesity medications. In April 2025, CMS chose not to finalize the proposal. Medicare therefore covers a GLP-1 only when it is prescribed for diabetes, cardiovascular disease, or another eligible diagnosis. Broadly changing the law would take an act of Congress.

When is a GLP-1 covered under Part D?

The same molecule can be covered or excluded depending on the diagnosis. Under current policy, Part D can cover an anti-obesity medication only when it treats another medically accepted condition. Examples are type 2 diabetes, or reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

Patients are often surprised to learn that GLP-1 drugs prescribed for type 2 diabetes, obstructive sleep apnea, or to lower cardiovascular risk may already be covered through their regular Part D plan.

The exact same therapy aimed only at the number on the scale is not. If you have one of those diagnoses, ask your prescriber whether your plan's formulary covers your medication for that indication.

The Medicare GLP-1 Bridge: $50/month starting July 2026

Starting in July 2026, some people with Medicare can get coverage for certain weight-loss medications through the new Medicare GLP-1 Bridge. CMS runs this short-term demonstration. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026, to December 31, 2027.

Eligible beneficiaries pay $50 for a month of GLP-1 medication. The $50 copays won't count toward Part D deductibles or the $2,100 cap on out-of-pocket spending.

The Bridge runs separately from your normal drug plan, outside the Part D coverage and payment flow. Part D plan sponsors carry no risk for GLP-1 products furnished under the demonstration. A central CMS processor handles approvals and payments instead of your plan.

Which medications are included?

The Bridge covers specific GLP-1 medications with FDA approval for weight loss. These are Foundayo, Wegovy (injection and tablets), and Zepbound (KwikPen). Ozempic and Mounjaro are not included.

Who qualifies?

Eligibility depends on your enrollment and clinical history. The clinical criteria are:

A body mass index (BMI) of 35 or greater.
A BMI of 30 or greater with heart failure, uncontrolled hypertension, or chronic kidney disease.
A BMI of 27 or greater with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

You also have to be enrolled in a Medicare Part D prescription drug plan. Medicare Advantage plans that include drug coverage count.

If you've already started a GLP-1 and lost weight, the criteria are checked as of when you first started therapy. That includes people who started before enrolling in Medicare Part D or before the July 1, 2026 launch of the Bridge.

One exception applies. If your diagnosis already qualifies for normal Part D coverage, you use that instead. Type 2 diabetes, obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) qualify. People with these diagnoses get GLP-1s through their Part D plan. They are ineligible for the Bridge, even if they meet its clinical criteria.

How the process works

Your doctor handles the paperwork. You need prior authorization, but it does not go through your regular Part D plan. Your doctor sends the prescription to a central system run by a CMS contractor, which already serves another Medicare drug program. Once approved, you pay the flat $50 copayment at the pharmacy when you pick up the prescription.

Which brands does Medicare cover: Wegovy, Zepbound, Ozempic, Mounjaro?

The weight-loss brands (Wegovy and Zepbound) are covered through the Bridge for the $50 copay, while the diabetes brands (Ozempic and Mounjaro) are covered by regular Part D only for diabetes, not weight loss.

For the full drug-by-drug breakdown, including the Wegovy pill, Foundayo, and which Medicare plans (Aetna, Humana, UnitedHealthcare) apply, see our guide: Does Medicare cover Zepbound, Wegovy, Ozempic, or Mounjaro?

How these medications actually work

GLP-1 receptor agonists mimic a natural gut hormone. In the brain, they act on regions that control appetite and change neurotransmitter and peptide release, which regulates hunger and energy expenditure. In the body, they raise insulin secretion, lower glucagon release, slow gastric emptying, and regulate gut hormones.

In plain terms, they help you feel full sooner, stay full longer, and steady your blood sugar. That is why the same drug class treats diabetes, cardiovascular risk, and obesity.

What about beyond 2027?

The Bridge is temporary by design. It covers the gap before a longer-term program that might begin in 2028, or might not. A broader effort called the BALANCE Model has been proposed, but its Medicare Part D rollout has been delayed.

For now the Bridge is the concrete option. If you want predictable long-term access, plan ahead with your clinician instead of assuming coverage will continue.

Frequently asked questions

Does Medicare cover Wegovy or Zepbound for weight loss?

Not through standard Part D when prescribed only for weight loss. However, beginning July 1, 2026, eligible beneficiaries can access certain weight-loss GLP-1s, including Wegovy and the Zepbound KwikPen, for a $50 monthly copay through the temporary Medicare GLP-1 Bridge if they meet the clinical criteria.

Will Medicare cover my GLP-1 if I have diabetes?

Potentially yes. GLP-1s prescribed for a medically accepted indication like type 2 diabetes or cardiovascular risk reduction may be covered under your regular Part D plan, subject to your plan's formulary and rules like prior authorization. Coverage always depends on your specific plan.

Are compounded GLP-1 medications covered by Medicare?

No. Compounded medications are not covered under the Bridge, which is limited to specific FDA-approved products, and compounded drugs are not FDA-approved. They remain a self-pay option for many patients who don't qualify for Bridge coverage.

Your options with TOM Weight Loss

Not everyone will qualify for the Bridge. Our clinic, led by Dr. Le, offers all-inclusive memberships with compounded semaglutide or tirzepatide and the medication included, plus an à la carte plan for brand-name GLP-1s.

(Compounded medications are not FDA-approved and are not the same as brand-name drugs.) To see how the Bridge applies to you, read our Medicare GLP-1 bridge guide and how it works pages.

Ready to talk it through? Start your consultation and we'll help you find an affordable path, whether that's Medicare coverage, brand-name, or a membership plan.